NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) issued its quarterly earnings results on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to analyst estimates of $3.23 million. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

4 equities research analysts have issued 1 year price objectives for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $31.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 112.0% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

News stories about KALV stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 725,700 shares, a decrease of 17.3% from the January 15th total of 877,600 shares. Based on an average daily trading volume, of 137,400 shares, the days-to-cover ratio is currently 5.3 days. Approximately 5.8% of the shares of the company are short sold. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Odonate Therapeutics (ODT), Karyopharm Therapeutics (KPTI), Dermira (DERM), Myovant Sciences (MYOV), Kiniksa Pharmaceuticals (KNSA), Gossamer Bio (GOSS), I-Mab (ARQT), Phathom Pharmaceuticals (PHAT), Achillion Pharmaceuticals (ACHN), Cytokinetics (CYTK), Radius Health (RDUS), Stoke Therapeutics (STOK), Endonovo Therapeutics (ENDV), Amphastar Pharmaceuticals (AMPH) and Applied Therapeutics (APLT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Ritter Pharmaceuticals (RTTR), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT) and TG Therapeutics (TGTX).

Kalvista Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (9.35%), Pictet Asset Management Ltd. (3.49%), Franklin Resources Inc. (1.59%), Victory Capital Management Inc. (1.54%), Victory Capital Management Inc. (1.54%) and State Street Corp (1.30%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Institutional Ownership Trends for Kalvista Pharmaceuticals.

KALV stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Algert Global LLC, Bank of America Corp DE and Bank of New York Mellon Corp. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par. View Insider Buying and Selling for Kalvista Pharmaceuticals.

KALV stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Victory Capital Management Inc., Victory Capital Management Inc., Ikarian Capital LLC, Pictet Asset Management Ltd., Public Sector Pension Investment Board and Janus Henderson Group PLC. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha and Daniel B Soland. View Insider Buying and Selling for Kalvista Pharmaceuticals.

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $14.15.

Kalvista Pharmaceuticals has a market capitalization of $252.29 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]